Pharmacoeconomics and Health Technology Assessment - GDKSF12
Title: Farmakoekonomika a hodnocení zdravotnických intervencí
Guaranteed by: Department of Social and Clinical Pharmacy (16-16220)
Faculty: Faculty of Pharmacy in Hradec Králové
Actual: from 2018
Semester: both
Points: 0
E-Credits: 0
Examination process:
Hours per week, examination: 0/0, Ex [HT]
Capacity: winter:unknown / unknown (unknown)
summer:unknown / unknown (unknown)
Min. number of students: unlimited
4EU+: no
Virtual mobility / capacity: no
Key competences:  
State of the course: taught
Language: Czech
Teaching methods: full-time
Level:  
Note: course is intended for doctoral students only
enabled for web enrollment
you can enroll for the course in winter and in summer semester
Guarantor: PharmDr. Jiří Klimeš, Ph.D.
Examination dates   WS schedule   
Annotation -
The aim is to prepare students to have overview with complex evaluation of health interventions (technologies), namely drugs, concerning their relative/comparative efficacy, safety and cost-effectiveness. The health economics aspects will be stressed in this subject, the most. These aspects are integrated within HTA (Health Technology Assessment), which represents an important objective tool for fair and balanced definition and understanding of the added value of drugs (and health technologies in general). In developed countries across the globe, HTA systems are commonly applied as a part of regulatory and decision-making processes, including pricing and reimbursement of health technologies and/or their inclusion and positioning in national formularies, guidelines, or therapeutic standards. In the Czech Republic and other European countries the environment in terms of HTA development is under cultivation. The demand for knowledge and methods in this healthcare areas has been growing both at the site of public authorities (e.g. ministry of health, drug agency), 3rd party payers i.e. insurance funds, healthcare providers and healthcare (pharmaceutical, medical devices) industry. The topics presented and discussed will focus on current HTA practices and they also follow-up on particular chapters taught in social pharmacy subject.
Last update: Klimeš Jiří, PharmDr., Ph.D. (24.10.2021)
Literature -

Obligatory:

  • Kobelt, G. Health Economics: An Introduction to Economic Evaluation, Monograph: https://www.ohe.org/publications/health-economics-introduction-economic-evaluation

  • BERGER, M. L.; BINGEFORS, K. and HEDBLOM, E. C. . Health care cost, quality, and outcomes: ISPOR book of terms.. Lawrenceville, NJ: ISPOR: Lawrenceville, NJ: ISPOR, 2003, s. ISBN 0974328901.

Recommended:

Last update: prepocet_literatura.php (14.08.2025)
Requirements to the exam -


Conditions for successful completion of the course:

1) Credit: 100% participation in seminars

2) Exam: group project + colloquium - below topics Areas for the final colloquium:

topics Areas for the final colloquium:

·         Funding and organization of health care, focus on pharmaceuticals

·         HTA (Health Technology Assessment) characteristics, definition

·         Health economics and pharmacoeconomics – rationale and definition of basic terms

·         Type of pharmacoeconomics studies

·         Regulatory processes: marketing authorization vs. reimbursement and patient access

·         Clinical evidence interpretation (clinical studies, meta-analyses, indirect comparisons) and Evidence hierarchy, sources of evidence-base medicine

·         Type of outcomes, clinical, surrogates, QALY (Quality-Adjusted Life-Year),  PRO (patient reported outcomes)

·         Pharmacoeconomic modelling: reasons, approaches, methods

.         RWE (Real world evidence) – applicability, generation and importance in the life-cycle of medicinal product
Last update: Klimeš Jiří, PharmDr., Ph.D. (24.10.2021)